Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safety issues in using complementary and alternative medicine.

Maurie Markman1

  • 1Department of Hematology/Medical Oncology and Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. markman@ccf.org

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|September 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.

Cell reports. Medicine·2026
Same author

Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing <i>ALK</i> Alteration Prolongs Treatment Duration.

JCO precision oncology·2026
Same author

The critical need for robust decision support in the era of precision cancer therapeutics.

Exploration of targeted anti-tumor therapy·2026
Same author

What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer.

Gynecologic oncology·2022
Same author

Treatment of Patients With Lobular Breast Cancer Harboring Human Epidermal Growth Factor Receptor 2 Mutation With HER2-Directed Therapy.

JCO precision oncology·2022
Same author

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery.

Gynecologic oncology reports·2020

Complementary and alternative medicine (CAM) use is rising among cancer patients, but potential toxicities are not well-documented. This review highlights known side effects, urging oncologists to stay informed about patient CAM use and associated risks.

Area of Science:

  • Oncology
  • Integrative Medicine
  • Medical Toxicology

Background:

  • Increasing patient use of complementary and alternative medicine (CAM) in cancer care.
  • Limited published data on the potential toxicities associated with various CAM strategies.

Purpose of the Study:

  • To review the medical literature and identify potential side effects of CAM.
  • To inform oncologists about the risks associated with CAM use in cancer patients.

Main Methods:

  • Systematic review of the medical literature.
  • Focused on identifying documented adverse events and toxicities of CAM.

Main Results:

  • While many CAM approaches are safe, significant toxicities have been reported.

Related Experiment Videos

  • Documented adverse events include emesis, hypersensitivity, cardiovascular and neurologic dysfunction, hepatic/renal failure, and secondary malignancies.

    • Conclusions:

    • Oncologists must be aware of nonprescription CAM products used by patients.
    • Understanding the potential toxicities of these agents is crucial for patient safety and integrated care.